Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

Eloxx Pharmaceuticals (NASDAQ: ELOX) has announced its participation in the Oppenheimer 33rd Annual Healthcare Conference, scheduled for March 13, 2023, at 12:00 PM ET. A live webcast and replay of the presentation will be accessible on their website.

The company focuses on ribosomal RNA-targeted genetic therapies and is advancing its lead candidate, ELX-02, through Phase 2 clinical trials for treating Alport syndrome linked to nonsense mutations. Eloxx is also engaged in preclinical efforts targeting rare diseases, including specific cancers and kidney disorders. For more details, visit www.eloxxpharma.com.

WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it will present at the Oppenheimer 33^rd Annual Healthcare Conference on Monday, March 13^th at 12:00 PM ET.

A live webcast of the presentation and a replay of the presentation will be available on the Company’s website at https://investors.eloxxpharma.com/events-presentations.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging its innovative TURBO-ZM™ chemistry technology platform in an effort to develop novel Ribosome Modulating Agents (RMAs) and its library of Eukaryotic Ribosome Selective Glycosides (ERSGs). Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in Phase 2 clinical development for the treatment of Alport syndrome in patients with nonsense mutations. Eloxx also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders.

For more information, please visit www.eloxxpharma.com.

Contact

Investors
John Woolford
john.woolford@westwicke.com
443.213.0506

Media
Laureen Cassidy
laureen@outcomescg.com

SOURCE: Eloxx Pharmaceuticals, Inc.

FAQ

When will Eloxx Pharmaceuticals present at the Oppenheimer Healthcare Conference?

Eloxx Pharmaceuticals will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 12:00 PM ET.

How can I watch the Eloxx Pharmaceuticals presentation?

The presentation will be available via a live webcast and replay on Eloxx's website at www.eloxxpharma.com.

What is the main focus of Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals specializes in ribosomal RNA-targeted genetic therapies for rare diseases.

What is ELX-02 and what is its current development status?

ELX-02 is Eloxx's lead investigational drug candidate, currently in Phase 2 clinical development for treating Alport syndrome.

What types of diseases are being targeted by Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals targets rare diseases, including inherited conditions, certain cancers, kidney diseases, and rare ocular genetic disorders.